TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Sustained response to ITP treatments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration / Minimal Inhibitory Concentration ratio (AUC/MIC ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacteria Load (log10)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Monocyte TNFα production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hypocalcaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Voice dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective response rate (ORR) Abemaciclib/Arm 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Objective response rate (ORR) Abemaciclib and MK-6482/Arm 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Abemaciclib and MK-6482/Arm 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identify known and novel immune defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Decrease of deformation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain Activation (BOLD Signal)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Magnitude, extent and location of brain activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: AUC of ACT-541468
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extended-Spectrum Days Of Antibacterial Therapy (ES-DOT) Per Empiric Day
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to Onset of 12-week Composite Confirmed Disability Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemical parameters (ErbB4 and Nrg4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemical parameters (IL-6, IL-10, nitric oxide synthase (NOS) 2 and Arg1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Symptom & Function Reports
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of patients with treatment-related intolerance
Endpoint domain: Adverse events/effects
Primary endpoint: Change in experimental pain from heat pulses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in experimental pain from mechanical stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Ki-67 protein expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Small-for-Gestational-Age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length-for-Age Z scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in number of acute surgeries
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: change in days of acute inpatient treatment
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Neonatal Pain, Agitation, and Sedation scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Receipt of Second Transfusion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Median Difference in Units pRBCs (for Those Transfusion-dependent)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Hospitalizations (for Both Transfusion Groups)
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Percentage of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of unexpected adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: serum HBsAg level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Safety
Endpoint domain: Adverse events/effects
Primary endpoint: Glasgow Outcome Scale - Extended (GOSE) at 6 Months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: SF-12v2 Health Survey at 6 Months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 6 Month Quality of Life in Brain Injury (Qolibri-OS) <52 (Impaired)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: prevention of relapse of upper GI symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bladder dysfunction evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Adverse events including Dose Limit Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Treatment-emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Treatment-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Circadian phase shift
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: brain activation on fMRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Microbiome constituents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with a clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Change Between Metastatic and Benign Nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: CD4 Count Absolute
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD4 Percent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Viral Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Upper-limb motor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage error rate in predicting arterial values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respiratory Function Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Respiratory Muscle Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Deep venous thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Proportion of individuals with L.donovani asymptomatic infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in weight in pounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Complete miscarriage
Endpoint domain: Mortality/survival
Primary endpoint: Surgical site infections within the first 30 days
Endpoint domain: Adverse events/effects
Primary endpoint: Transition rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Area Under the Concentration-Time Curve (AUC) from the time of dosing to the last quantifiable concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC from the time of dosing to infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerance and toxicity profile
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Clinically Significant AdV Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Change in peak exercise pulmonary oxygen uptake (peak V02)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: numbers of newborn with ALD
Endpoint domain: Mortality/survival
Primary endpoint: numbers of immune cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: cumulative number of hospitalisation
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of Participants With Stable Platelet Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Bioimpedance Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Strengths and Difficulties questionnaire (SDQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Functional changes of critical brain regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Coronary reserve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in brain functional MRT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: PDRP changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute postoperative pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall clinical cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of office hysteroscopy detection of cervical lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-Day Safety
Endpoint domain: Adverse events/effects
Primary endpoint: Total standardized daily dose (TSDD) from medical records
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total standardized daily dose (TSDD) - self-report medication inventory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in Troponin -I values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline in Sheehan - Suicidality Tracking Scale (S-STS) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Safety assessed by nature, frequency and severity of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics (PK) of ASP1707 measured by area under the plasma concentration - time curve (AUC) extrapolated to time = infinity (AUCinf) in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacodynamics (PD) of ASP1707 measured by Cmax in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total morphine administered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of women who select home-use of mifepristone
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction with Method
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: % Predicted Forced Vital Capacity (FVC) Absolute Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Participant Preference
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Occurrences of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrences of serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Overall rate of clinical:molecular primary tumor subtype incongruence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Impact of Whole Exome Sequencing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Impact of Information Derived from Exome Sequencing
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Delay in initiating postoperative radiation therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Collection efficiency of peripheral blood stem cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Presence of neuromuscular junctions fragmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Presence of axonal sprouting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: neuropharmacodynamic effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of DLTs
Endpoint domain: Adverse events/effects
Primary endpoint: Resolution of hypercapnia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pain intensity measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drinks Per Drinking Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 28-day neonatal mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: Philadelphia Naming Test (PNT) performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Total postoperative analgesic consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Prospective Memory Test
Endpoint domain: Cognitive functioning
Primary endpoint: Planning Tasks
Endpoint domain: Cognitive functioning
Primary endpoint: Shifting Task
Endpoint domain: Cognitive functioning
Primary endpoint: Updating task
Endpoint domain: Cognitive functioning
Primary endpoint: Participant acceptability and satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ground reaction force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose limited toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Density Score of Coronary Artery Calcification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vaginal microbiota difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hammersmith Functional Motor Scale Expanded (HFMSE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gross Motor Function Scale (GMFM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep apnea severity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Confirmed Varicella Case
Endpoint domain: Adverse events/effects
Primary endpoint: Safety information
Endpoint domain: Adverse events/effects
Primary endpoint: Lumbar Spine Areal Bone Mineral Density (BMD) Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trough Serum Calcium Level Exceeding Limits
Endpoint domain: Adverse events/effects
Primary endpoint: Trough Albumin-Corrected Calcium Level Exceeding Limits
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Hospitalization for Heart Failure (HHF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With All-cause Mortality (ACM)
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence of treatment emergent AEs (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants whose personal vaccines can be manufactured and delivered without unacceptable toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Achieving High Flow Low Pressure on Cardiopulmonary Bypass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Panretinal Leakage Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC0-∞) of NNC172-2021
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BPAR
Endpoint domain: Adverse events/effects
Primary endpoint: Pulse wave velocity augmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Neural activity in prefrontal regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to first occurrence of major adverse cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum observed plasma concentration of abiraterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach the maximum observed plasma concentration of abiraterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration of abiraterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in hemodynamic measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Dose-limiting toxicities including incidence of Treatment-Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Response Evaluation Criteria in Solid Tumors using RECIST v1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With Complete Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to First Relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive results
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in net whole-body protein synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Vaccine Safety
Endpoint domain: Adverse events/effects
Primary endpoint: Tooth whiteness index (WIO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of pre-eclampsia (PE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Prevalence of fetal growth retardation (FGR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Prevalence of gestational diabetes (GDM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Achilles questionnaire (VISA-A)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence, severity and causality of adverse events (AEs) and serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Best overall response rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MTEV recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Total Chest X Ray Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Whole-muscle Activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Net whole body protein metabolism synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence of Pulmonary Lymphoepithelioma-like Carcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Bilioenteric anastomotic leakage
Endpoint domain: Adverse events/effects
Primary endpoint: Self-reported expenses
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Di-Dimer Increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Treatment-Related Adverse Events of Etanercept
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Serious Treatment-Related Adverse Events of Etanercept
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Unlisted Treatment-Related Adverse Events of Etanercept
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Good Responders and Moderate Responders Among Participants With EULAR Response Based on DAS28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical progression of VHL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic progression of VHL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount drug self-administered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic Capability Ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Reporting one or More Treatment-emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Dose-Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting One or More Treatment Emergent Serious Adverse Event (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative Delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 12-month changes in drug-misuse status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygenation Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Relationship Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in WOMAC score for OA knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes